Application of ventricular tachyarrhythmia definitions of the updated Lambeth Conventions provides incompatibility with earlier results, masks antifibrillatory activity and reduces inter-observer agreement. by Regev, A. et al.
INTRODUCTION
Sudden cardiac death caused by ventricular arrhythmias is a
major public health problem in modern industrialized countries
(1), which emphasizes the importance of arrhythmia research.
Currently, there are clinical (1, 2) and experimental guidelines
(3, 4) dealing with arrhythmia research and management, but
these guidelines do not use unified arrhythmia definitions, and
that is a notable problem when we try to objectively evaluate and
compare results of arrhythmia investigations.
The Lambeth Conventions (LC I), a guidance for research on
arrhythmias published in 1988 (3), had a substantial impact on the
experimental arrhythmia research; the paper has been cited more
than 1000 times since its publication 30 years ago according to the
database of Web of Science. However, the advances in technology,
development of monitoring and pharmacologic solutions and of
course the extensive research about arrhythmias had finally led to
the realization that LC I was in need to be updated. Thus, a
meeting was held in London in 2010 to update the guidance. The
revised conventions were intended to be of practical value in terms
of the design, execution, and analysis of experiments, with
emphasis on the definition, classification, and quantification of
ventricular and atrial arrhythmias (4). The revised Lambeth
Conventions (LC II) were intended to be applied in preclinical and
clinical research. Authors of LC II invited investigators to state
whether or not they had used the conventions in their studies, and
to test their validity by experiment.
Importantly, there are substantial changes in the definitions of
the ventricular tachyarrhythmias between the original and the
updated Lambeth Conventions (Table 1). The new
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The Lambeth Conventions (LC I), a landmark guidance document for arrhythmia research was updated and arrhythmia
definitions were changed in the new Lambeth Conventions II (LC II). This study examined whether the arrhythmia
definitions of LC I and LC II yield the same qualitative results and whether LC II improves inter-observer agreement.
Two independent investigators performed blinded arrhythmia analysis of the electrocardiograms of isolated,
Langendorff rat hearts subjected to regional ischemia and perfused with Class I antiarrhythmics with 3 or 5 mM K+ in
the perfusate. Data obtained with arrhythmia definitions of LC I and LC II were compared within and between observers.
Applying ventricular fibrillation (VF) definition of LC II significantly increased VF incidence and reduced VF onset
time irrespective of treatment by detecting ‘de novo’ VF episodes not found by LC I. LC II reduced the number of
ventricular tachycardia (VT) episodes and simultaneously increased the number of VF episodes as compared with the
respective values obtained according to LC I. Using VF definition of LC II masked the significant antifibrillatory effects
of flecainide and the high K+ concentration identified with the VF definition of LC I. When VF incidence was tested, a
very strong inter-observer agreement was found according to LC I, whereas using VF definition of LC II reduced inter-
observer agreement. It is concluded that LC II shifts some tachyarrhythmias from VT to VF class, and thus results
obtained by arrhythmia definitions of LC I and LC II are not compatible; VF definition of LC II may change the
conclusion of pharmacological, physiological and pathophysiological arrhythmia investigations and may reduce inter-
observer agreement. Thus, VT and VF definitions of LC II should be amended in order to increase compatibility and
inter-observer agreement.
K e y  w o r d s : Lambeth Conventions, arrhythmia definitions, ventricular fibrillation, incompatibility of the results, inter-observer
agreement
tachyarrhythmia definitions imply that some arrhythmias
classified as ventricular tachycardia (VT) according to LC I are
now classified as ventricular fibrillation (VF) according to LC II.
This suggests that the new definitions change the results and -
more importantly - the conclusion of arrhythmia studies. Thus,
the aim of the present study was to examine whether the
arrhythmia definitions of LC I and LC II are compatible, and
yield the same qualitative arrhythmia results. Also, it was tested
whether arrhythmia definitions of LC I or LC II allow better
inter-observer agreement. Thus, two independent investigators
reanalysed the electrocardiogram (ECG) recordings of
experiments done earlier by Farkas and Curtis (5), and performed
a retrospective, blinded analysis of the number and incidence of
ventricular arrhythmias in isolated, Langendorff perfused rat
hearts subjected to regional ischemia and treated with Class I
antiarrhythmic agents. The arrhythmia data obtained by applying
arrhythmia definitions of LC I and LC II were compared to test
the compatibility between the arrhythmia definitions of LC I and
LC II. Also, inter-observer agreement was determined to
investigate whether arrhythmia definitions of LC I or LC II allow
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Arrhythmia Definition according to 
Lambeth Conventions I (3) 
Definition according to 
Lambeth Conventions II (4) 
Ventricular premature beat 
(VPB) 
Isolated ventricular premature 
beats are defined as discrete 
and identifiable premature 
QRS complexes (premature 
in relation to the P wave). 
A VPB is defined as a 
ventricular electrical complex 
(complete electrical event: 
QRS, RS, QRST or RST) that 
is different in shape (voltage 
and/or duration, i.e., height 
and/or width) from the 
preceding (non-VPB) 
ventricular complex, and is 
premature in relation to the 
preceding ventricular 
complex. 
Bigeminy Bigeminy is characterised by 
the minimum sequence: P, 
QRS, VPB, P, QRS, VPB. 
Bigeminy has the minimum 
sequence VPB, normal sinus 
beat, VPB (which may be 
repeated) in which the VPBs 
have the same shape and 
timing. 
Salvo Two or three consecutive 
VPBs do not constitute 
ventricular tachycardia but 
should be termed a salvo. 
A run of two or three 
consecutive VPBs is defined 
as a salvo. 
Ventricular tachycardia 
(VT) 
A run of 4 or more 
consecutive ventricular 
premature beats. 
A sequence of a minimum of 
4 consecutive ventricular 
complexes. 
Monomorphic VT: 
peak-peak interval, height 
and intrinsic shape are 
constant. 
Polymorphic VT: 
the peak-peak interval and/or 
height and/or intrinsic shape 
vary, and the variation of any 
or each of these is 
progressive. 
Ventricular fibrillation 
(VF) 
A signal for which individual 
QRS deflections can no 
longer be distinguished from 
one another (implying 
morphological instability) 
and for which a rate can no 
longer be measured. 
A sequence of a minimum of 
4 consecutive ventricular 
complexes without 
intervening diastolic pauses, 
in which intrinsic shape, 
peak-peak interval and height 
vary, and the variation 
between each is non-
progressive. It is the non-
progressive nature of the 
variation of all 3 variables 
that distinguishes VF from 
polymorphic VT and torsades 
de pointes.  
 
Table 1. Comparison of the definitions of ventricular arrhythmias between the Lambeth Conventions I and II.
better agreement on the arrhythmia results between the two
independent observers.
MATERIALS AND METHODS
General experimental procedure
For detailed methodical description see the published study
by Farkas and Curtis (5), from which the raw ECGs were
obtained for arrhythmia analysis. Thus, here only a short
description of the experiments is added as follows.
The animal-handling protocol was in accordance with the
Guidance of the Operation on the Animals (Scientific
Procedures) Act 1986, London, UK. Male rats were anesthetized
with pentobarbitone (60 mg/kg intraperitoneally). Hearts were
excised, and then perfused according to Langendorff with
modified Krebs solution containing 118.5 mM NaCl, 25.0 mM
NaHCO3, 1.2 mM MgSO4, 1.2 mM NaH2PO4, 1.4 mM CaCl2, 3
mM KCl (or 5 mM where indicated), and 11.1 mM glucose.
Perfusion solution was delivered at 37ºC and pH 7.4; perfusion
pressure was maintained constant at 70 mm Hg. The left main
coronary artery was occluded by a silk suture for 30 min. A
unipolar ECG was recorded using a MacLab system
(ADInstruments Ltd., Oxford, UK) (5-7).
Drug administration protocol, groups of hearts
In the first two sets of experiments, Krebs’ solution contained
3 mM K+. In the third and fourth sets of experiments, K+
concentration was elevated to 5 mM. Each set of experiments
contained four groups of hearts: one control and three drug-treated
groups, each treated with one concentration of a representative
Class I antiarrhythmic (quinidine, lidocaine or flecainide). One
lower and one higher concentration of quinidine (0.79 and 7.90
µM), lidocaine (3.88 and 12.93 µM), and flecainide (0.74 and 1.48
µM), representing the peak unbound plasma and total blood
concentrations, respectively, at ‘therapeutic’ dosage, were
evaluated in the first two sets of experiments and also in the last
two sets of experiments. Each group contained 12 hearts in the first
two sets of experiments (96 hearts in total; 3 mM K+ in the Krebs),
whereas every group in the third and fourth sets of experiments
contained 6 hearts (48 hearts in total, 5 mM K+ in the Krebs).
Experiments were done in a randomized and blinded manner.
Reanalysing ischaemic arrhythmias according to definitions 
of LC I and LC II, measurement of the number and incidence 
of tachyarrhythmias
The ECG recordings of the original investigation done by
Farkas and Curtis (5) were reanalysed by two independent
investigators using LabChart7 (ADInstruments Ltd., Oxford,
UK). The two investigators were well trained and equally
experienced in evaluating ECG. Ventricular arrhythmias were
defined according to the LC I for the primary evaluation (Table
1). The number of VT and VF episodes, the incidence and the
time to onset of VT and VF were determined from the ECG
recorded during the 30-min-long ischaemia. Then the whole
analysis was repeated according to the arrhythmia definitions of
LC II (Table 1). All variables were measured in a blinded manner.
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Fig. 1. Comparison of the percent incidences of ischaemic ventricular fibrillation (VF) obtained from the 1st set of experiments by two
independent observers (Observer A and Observer B) using VF definition of Lambeth Conventions I (LC I) and Lambeth Conventions
II (LC II). Langendorff perfused rat hearts were subjected to local ischaemia for 30 min. Hearts were perfused with the low
concentration of quindine (0.79 µM), lidocaine (3.88 µM), flecainide (0.74) or solvent (Control), each group contained n = 12 hearts,
Krebs solution contained 3 mM K+. *P < 0.05 versus Control.
Statistical analysis
Continuous variables were expressed as means ± SEM. Within
group comparison of continuous data (e.g. the number of
arrhythmia episodes, the onset times of VT and VF) were
performed with the non-parametric Wilcoxon test for paired
samples. Arrhythmia incidences were expressed as percent values,
and were compared with Fisher’s exact test with the Bonferroni
correction, that is, the P values of Fisher’s exact test were
multiplied by the numbers of comparisons to allow multiple
comparisons (8). A P value < 0.05 was taken as indicative of a
statistically significant difference between values. The intra-
observer agreement on arrhythmia incidence data obtained
according to LC I and LC II was assessed with Cohen’s kappa
statistic (9). Similarly, the inter-observer agreement on VT and VF
incidence data among independent observers was calculated with
Cohen’s kappa statistic (9).
RESULTS
Ischaemic ventricular fibrillation incidence in the first set 
of experiments (3 mM K+, low concentrations of drugs)
When the arrhythmia definitions of LC I were applied, both
of the two independent investigators found that VF was
frequently induced in the control group, and only flecainide was
able to reduce VF incidence significantly at the applied low
concentration (Fig. 1). These results are in a good accordance
with the arrhythmia results of the original investigation obtained
by a different observer using the same arrhythmia definitions of
LC I (5). This means that applying arrhythmia definitions of LC
I allowed the two independent investigators to reproduce
previous results.
When arrhythmia definitions of LC II were applied, both of
the two independent investigators found that VF was induced in
all control hearts, and none of the drugs affected significantly VF
incidence at the applied low concentrations (Fig. 1). Thus, the
significant antifibrillatory effect of the low concentration of
flecainide was masked when arrhythmia definitions of LC II
were used. This means that results about the antifibrillatory
effect of flecainide qualitatively differ from those obtained by
applying arrhythmia definitions of LC I.
Ischaemic ventricular fibrillation incidence in the second set of
experiments (3 mM K+, high concentrations of drugs)
When the arrhythmia definitions of LC I were applied, both of
the two independent investigators found that VF was frequently
induced in the control group, and all three drugs reduced VF
incidence significantly at the applied high concentrations (Fig. 2).
These results well accord with the arrhythmia results of the
original investigation obtained by a different observer using the
same arrhythmia definitions of LC I (5). This means that applying
arrhythmia definitions of LC I allowed the two independent
investigators to reproduce previous results.
When the arrhythmia definitions of LC II were applied,
Observer B found that the high concentrations of all three drugs
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Fig. 2. Comparison of the percent incidences of ischaemic ventricular fibrillation (VF) obtained from the 2nd set of experiments by two
independent observers (Observer A and Observer B) using VF definition of Lambeth Conventions I (LC I) and Lambeth Conventions
II (LC II). Langendorff perfused rat hearts were subjected to local ischaemia for 30 min. Hearts were perfused with the high
concentration of quindine (7.90 µM), lidocaine (12.93 µM), flecainide (1.48 µM) or solvent (Control), each group contained n = 12
hearts, Krebs solution contained 3 mM K+. *P < 0.05 versus Control.
reduced the incidence of ischaemic VF as compared with
control, which accords with the results obtained according to LC
I (Fig. 2). However, Observer A found that the applied high
concentration of flecainide did not significantly reduce the
incidence of ischaemic VF, which qualitatively differs from the
results obtained according to LC I, and it also contradicts the
results of Observer B (Fig. 2).
Ischaemic ventricular fibrillation incidence in the control hearts,
the effect of K+ concentration on ventricular fibrillation incidence
Ischaemic VF incidence was compared between the control
group of hearts perfused with 3 mM K+ (the hearts of the control
groups of the 1st and 2nd sets of experiments) and the control
hearts perfused with 5 mM K+ (the hearts of the control groups
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Fig. 3. Comparison of the percent incidences of ischaemic ventricular fibrillation (VF) between control rat hearts subjected to local
ischaemia for 30 min and perfused with Krebs solution containing 3 or 5 mM K+ (n = 24 and n = 12 hearts, respectively). Two
independent observers (Observer A and Observer B) performed the blinded arrhythmia analysis using VF definition of Lambeth
Conventions I (LC I) and Lambeth Conventions II (LC II). *P < 0.05 versus 3 mM K+.
Fig. 4. The total number of hearts
with ischaemic ventricular
fibrillation (VF) out of the 144
Langendorff perfused rat hearts
subjected to local ischaemia for
30 min irrespective of the drug
treatment and the K+ content of
the perfusate. VF was diagnosed
by applying VF definitions of
Lambeth Conventions I (LC I)
and Lambeth Conventions II (LC
II). Observer A and Observer B
are the two independent
observers. The number in the
common part of the LC I and LC
II classes shows the total number
of hearts that experienced VF
according to both LC I and LC II.
of the 3rd and 4th sets of experiments). Both investigators found
that the elevation of the K+ concentration from 3.0 mM to 5.0
mM significantly reduced the incidence of ischaemic VF, when
arrhythmia definitions of LC I were applied (Fig. 3). These
results well accord with the arrhythmia results of the original
investigation obtained by a different observer using the same
arrhythmia definitions of LC I (5). Again, this shows that
applying arrhythmia definitions of LC I allowed the two
independent investigators to reproduce previous results.
However, the marked antiarrhythmic effect of the increased K+
concentration seen according to LC I was masked when
arrhythmia definitions of LC II were applied in the present
investigation, and these results did not differ qualitatively
between the two investigators (Fig. 3).
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Fig. 5. The effect of definitions of ventricular fibrillation (VF) of Lambeth Conventions I (LC I) and Lambeth Conventions II (LC II)
on the onset time of the first episode of ischaemic VF in Langendorff perfused rat hearts subjected to local ischaemia for 30 min and
experiencing VF according to both LC I and LC II. Parts (a) and (b): VF onset times in the 1st set of experiments, in which hearts were
perfused with the low concentration of quindine (0.79 µM), lidocaine (3.88 µM), or solvent (Control), Krebs solution contained 3 mM
K+. Part (c): VF onset times in the whole set of experiments irrespective of drug treatment and the K+ content of the perfusate. Observer
A and Observer B are the two independent observers. *P < 0.05 versus LC I.
            
                
            
            
              
                
               
        
 
Arrhythmia Observer Incidence  (%) Kappa 
95% Confidence 
interval  
  LC I LC II  for kappa  
VT A 85 84 0.974 0.922 – 1.000 
 B 88 76* 0.586 0.421 – 0.751 
VF A 35 60* 0.529 0.411 – 0.646 
 B 33 60* 0.482 0.365 – 0.599 
 
           
             
               
                    
Table 2. The percent incidences of ischaemic ventricular tachycardia and ventricular fibrillation irrespective of the drug treatment and K+
content of the perfusate in n = 144 Langendorff perfused rat hearts subjected to local ischaemia for 30 min. Intra-observer agreement on
the results obtained according to the arrhythmia definitions of Lambeth Conventions I and Lambeth Conventions II, results of the Cohen’s
Kappa statistical analysis.  Observers A and B are the two independent observers of the present investigation. LC I and LC II, VT and VF
incidence data obtained according to the arrhythmia definitions of Lambeth Conventions I and Lambeth Conventions II, respectively.
VT, ventricular tachycardia; VF, ventricular fibrillation; Kappa, kappa coefficient obtained by Cohen’s Kappa statistical analysis; note that
kappa value of 1.0 means perfect agreement, whereas the kappa value of 0.0 means absolutely no agreement; thus, the greater the kappa
value in the range of 0.0 – 1.0, the greater the agreement. *P < 0.05 versus LC I.
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Fig. 6. The numbers of ventricular tachycardia (VT) and ventricular fibrillation (VF) episodes and the cumulative number of VT and
VF episodes (VT + VF) in those eight hearts of the flecainide treated group of the first set of experiments, in which neither Observer
A nor Observer B found VF according to Lambeth Conventions I (LC I), but both of them identified VF according to Lambeth
Conventions II (LC II). Observer A and Observer B are the two independent observers. *P < 0.05 versus LC I. #P = 0.055 versus LC
I. Note that VF episodes found by applying VF definition of LC II are ‘de novo’ VF episodes, and occurred only as a result of
‘arrhythmia shift’, and ‘arrhythmia fragmentation’ did not contribute to their occurrence.
            
                
             
             
              
      
 
Incidence  
of Lambeth Convention Observers Kappa 
95% Confidence 
interval 
for kappa  
 
VT LC I A vs. O 0.918 0.826 – 1.000 
  B vs. O 0.615 0.424 – 0.805 
  A vs. B 0.652 0.471 – 0.833 
 LC II A vs. B 0.675 0.525 – 0.825 
     
VF LC I A vs. O 0.908 0.836 – 0.980 
  B vs. O 0.938 0.877– 0.998 
  A vs. B 0.938 0.879 – 0.998 
 LC II A vs. B 0.884 0.806 – 0.962 
 
           
             
                
         
 
Table 3. Inter-observer agreement on the incidences of ventricular tachycardia and ventricular fibrillation. Results of the Cohen’s Kappa
statistical analysis. LC I and LC II: VF and VT incidence data obtained according to the arrhythmia definitions of Lambeth Conventions
I and Lambeth Conventions II, respectively. Observers A and B are the two independent observers of the present investigation, Observer
O is the observer of the original investigation published by Farkas and Curtis (5).
VT, ventricular tachycardia; VF, ventricular fibrillation; Kappa, kappa coefficient obtained by Cohen’s Kappa statistical analysis. VT and
VF incidences were obtained irrespective of the drug treatment and K+ content of the perfusate from n = 144 Langendorff perfused rat
hearts subjected to local ischaemia for 30 min.
Ischaemic ventricular tachycardia and ventricular fibrillation
incidences in the whole investigation, and intra-observer
agreement
VT and VF incidences were calculated irrespective of the
treatment and the K+ content of the perfusate in the 144 hearts
of the whole investigation. Observer A did not find significant
effect of LC II on VT incidence, and achieved good intra-
observer agreement on VT incidence (Table 2). However,
Observer B found that applying arrhythmia definitions of LC II
significantly reduced VT incidence as compared with the
respective value obtained according to LC I, which resulted in
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Fig. 7. The numbers of ventricular tachycardia (VT) and ventricular fibrillation (VF) episodes and the cumulative number of VT and
VF episodes (VT + VF) in the n = 12 control hearts of the first set of the experiments. LC I and LC II: data obtained by using
arrhythmia definitions of Lambeth Conventions I and Lambeth Conventions II, respectively. Observer A and Observer B are the two
independent observers. *P < 0.05 versus LC I. Note, that the extra VF episodes found by applying VF definition of LC II can be the
result of ‘arrhythmia shift’. However, in theory, ‘arrhythmia fragmentation’ could also contribute to the increase in VF number
according to LC II, as VF episodes found by LC I could be fragmented into shorter episodes due to containing diastolic pauses.
 
 
              
             
                
                
                 
            
  
 Observer A Observer B 
 Number of hearts % Number of hearts % 
     
VF found in the same heart by both LC I and LC II 51 100 47 100 
VF onset time reduced by LC II 42 82 38 81 
VF onset time not affected by LC II 9 18 9 19 
VF onset time increased by LC II 0 0 0 0 
 
              
            
      
 
 
Table 4. The effect of applying the new definition of ventricular fibrillation of Lambeth Conventions II on the onset time of ischaemic
ventricular fibrillation in Langendorff perfused rat hearts. The onset time of ischaemic VF was examined in all hearts that experienced
VF irrespective of K+ content of the perfusate and drug treatment in the whole investigation (in all four sets of experiments utilising
n = 144 isolated rat hearts).
LC I and LC II, Lambeth Conventions I and II, respectively. VF, ischaemic ventricular fibrillation. Observer A and Observer B, the
two independent observers who performed blinded arrhythmia analysis of the experiments.
only moderate intra-observer agreement on VT incidence
(Table 2).
Both observers found that VF was diagnosed in a significantly
greater proportion of hearts, when the arrhythmia definitions of
LC II were applied, as compared with the respective value
measured according to the arrhythmia definitions of LC I (Table
2). Also, both observers found that when arrhythmia definitions of
LC II were applied, VF was diagnosed in all hearts, in which VF
was diagnosed according to LC I. However, there were many
hearts, in which VF was diagnosed only according to LC II and
VF was not found according to LC I (Fig. 4). Consequently,
Cohen’s kappa analysis showed that intra-observer agreement on
VF incidence data obtained according to LC I and LC II was only
moderate in case of both A and B Observers (Table 2).
The inter-observer agreement on ventricular tachycardia and
ventricular fibrillation incidences among independent observers
The inter-observer agreement on VT and VF incidences
among independent observers was calculated irrespective of the
treatment and the K+ concentration in the 144 hearts of the whole
investigation. Applying VT definition of LC II did not
remarkably improve the inter-observer agreement on VT
incidence between Observers A and B; moderate inter-observer
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Fig. 8. Incompatibility between the classes of the
ventricular fibrillation of the Lambeth Conventions
I (LC I) and Lambeth Conventions II (LC II). Part
(a): ventricular tachyarrhythmia diagnosed as
ventricular fibrillation (VF) according to both LC I
and LC II. Part (b): a ten-beat tachyarrhythmia
episode of ‘de novo’ VF as this ventricular
tachyarrhythmia is diagnosed as ventricular
tachycardia (VT) according to LC I, while the same
episode is diagnosed as VF according to LC II. LC
II emphasised the importance of ‘diastolic pause’.
According to LC II, “if an arrhythmia is interrupted
by an identifiable pause or quiescence (a ‘diastolic
pause’, or a flat isoelectrical line) that is longer than
the prevailing sinus rate (or idioventricular rate if
the AV node is blocked) then it makes more sense
to classify each arrhythmia present before and after
the pause as separate events” (4). Based on the
above recommendation of LC II, there is no
relevant diastolic pause between the ventricular
complexes of this tachyarrhythmia, thus this
arrhythmia should be regarded as one single run of
arrhythmia. Also note that the arrhythmia consists
of sections with four consecutive beats (beats 3-4-
5-6 and beats 7-8-9-10), in which neither intrinsic
shape, nor peek-peek interval, nor height of the
ventricular complexes change progressively, thus
each of these four-beat arrhythmia sections should
be classified as VF according to LC II (see Table 1
for the arrhythmia definitions). Convention 14 of
LC II states that “When rhythms segue from one to
another without an identifiable interruption or
quiescence, or vary between simultaneously
recorded leads, then the arrhythmia should be
classified as the most serious manifestation within
segue or lead” (4). As this arrhythmia in part b
should be regarded as one single run of arrhythmia
and VF is the most serious arrhythmia
manifestation within segue, the whole arrhythmia
should be classified as VF according to LC II. On
the other hand, QRS deflections can be
distinguished from one another and the rate can be
measured, thus the same arrhythmia should be
classified as VT according to LC I. Part (c): a four-
beat tachyarrhythmia episode of ‘de novo’ VF as
this ventricular tachyarrhythmia is diagnosed as VT
according to LC I, while the same episode is
diagnosed as VF according to LC II. The ECG
examples were recorded in three isolated,
Langendorff perfused rat hearts subjected to
regional ischaemia for 30 min.
agreement was found between them when VT incidence was
tested either according to LC I or according to LC II (Table 3).
Importantly, when VF incidence obtained according to LC I
was tested, very strong inter-observer agreements (high kappa
values) were found among the two independent investigators
(Observers A and B) and the investigator of the original
investigation (Observer O), (5) (Table 3). When arrhythmia
definitions of LC II were applied, a good agreement was found
in VF incidence between the two independent investigators;
however, the kappa value was lower than that obtained
according to LC I (Table 3).
The onset time of ischaemic ventricular fibrillation in the first set
of experiments
When hearts were perfused with the low concentrations of
the drugs and Krebs solution contained 3 mM K+ (first set of
experiments), VF incidences were high in the Control, Quinidine
and Lidocaine groups of hearts irrespective of the applied VF
definition (Fig. 1). This allowed us to examine the effect of the
applied arrhythmia definitions on the onset time of the first
episode of ischaemic VF in these three groups. Both observers
found that VF onset time was significantly reduced in these three
groups, when arrhythmia definitions of LC II were used as
compared with the respective values obtained by applying
arrhythmia definitions of LC I (Fig. 5a and 5b). This shows that
some ischaemic arrhythmias, which were not identified as VF
according to LC I, were identified as VF according to LC II, and
these arrhythmias were found not only in drug-free hearts but in
quinidine and lidocaine treated hearts, too. When VT definition
of LC II was applied, VT onset times were not significantly
affected in any of the groups as compared with the respective
values obtained by applying VT definition of LC I (data not
shown).
The onset time of ventricular fibrillation in all hearts that
experienced ventricular fibrillation irrespective of K+ content of
the perfusate and drug treatment
When all those hearts were examined that experienced
ischemic VF according to both LC I and LC II in the whole
investigation, the two independent observers found that applying
arrhythmia definitions of LC II significantly reduced the onset
time of the first episode of VF as compared with the value
obtained by using arrhythmia definitions of LC I (Fig. 5c).
Applying VF definition of LC II did not increase VF onset time
in any of the hearts, but reduced this variable in approximately
80% of the hearts (Table 4). These results did not differ
qualitatively between the two independent observers (Table 4).
The numbers of ventricular tachycardia and ventricular
fibrillation episodes
In order to examine whether applying arrhythmia definitions
of LC II causes an ‘arrhythmia shift’ from the VT class to the VF
class, the numbers of VT and VF episodes were calculated in the
control and the flecainide treated groups of the first set of
experiments (n = 12 hearts in each group). These two groups
were chosen, as the greatest and least number of arrhythmias
occurred in the Control and Flecainide groups, respectively.
First, a statistical analysis was performed on the data of those
eight hearts of the flecainide treated group of the first set of
experiments, in which neither Observer A nor Observer B found
VF according to LC I, but both of them identified VF according
to LC II. In the flecainide treated 8 hearts, both observers found
that applying VT definition of LC II reduced the number VT
episodes as compared with the respective values obtained by
using VT definition of LC I (Fig. 6). On the other hand, applying
VF definition of LC II significantly increased the number of VF
episodes as compared with the respective zero value obtained by
using VF definition of LC I (Fig. 6). Interestingly; Observer A
found that arrhythmia analysis according to LC II significantly
increased the cumulative number of VT and VF episodes as
compared with the respective value obtained according to LC I
in the flecainide treated 8 hearts. This suggests that when
arrhythmia analysis was performed according to LC II, VT
episodes were not only shifted to the VF class, but were also
fragmented (i.e. broken up into shorter episodes due to
containing diastolic pauses). Observer B did not find any
significant effect of LC II on the cumulative number of VT and
VF episodes (Fig. 6). Analysis of the number of the VT and VF
episodes in the 12 hearts of the control group of the first set of
experiments yielded qualitatively the same results despite
identifying VF episodes not only by LC II but LC I, too (Fig. 7).
DISCUSSION
Present results show that arrhythmia analysis according to
LC II qualitatively changed conclusions about pharmacological
effects of flecainide. The change in tachyarrhythmia definitions
also affected well documented pathophysiological effects, i.e.
the preventive effect of the high K+ concentration against
ischaemic VF disappeared when the VF definition of LC II was
applied. The reason behind these changes was that VF definition
of LC II identified ‘de novo’ VF episodes not identified
according to LC I, which is supported by the data showing that
application of the VF definition of LC II increased VF incidence
and reduced VF onset time. Importantly, a very strong inter-
observer agreement was found among the two independent
investigators, when VF incidence obtained according to LC I
was tested. Applying VF definition of LC II resulted in less inter-
observer agreement on VF incidence.
Arrhythmia shift from ventricular tachycardia to ventricular
fibrillation category enlarges the ventricular fibrillation class
of LC II and markedly increases sensitivity of ventricular
fibrillation detection
VF definition of LC II diagnosed VF in all hearts, in which
VF was identified according to LC I. Moreover, there were many
other hearts, in which VF was detected only according to LC II
and VF was not found according to LC I. Also, applying VF
definition of LC II did not increase VF onset time in any of the
hearts, however reduced this variable in the majority of the
hearts. These results show that the VF class of LC II
incorporated and enlarged the VF class defined by LC I. The
reason behind this is that VF definition of LC II not only
identified VF episodes detected by LC I, but also identified ‘de
novo’ VF episodes not detected according to LC I. Our results
clearly show that the enlarged VF category of LC II substantially
increased the sensitivity of VF detection.
Comparing tachyarrhythmia definitions of LC I and LC II
(Table 1) explains the mechanism of detection of ‘de novo’ VF
episodes according to LC II. While arrhythmias containing 4 or
more consecutive ventricular premature beats with non-
progressive variation in peak-peak interval, height and intrinsic
shape should be classified as VTs according to LC I, the same
arrhythmias are now shifted to the VF category of LC II (Fig. 8,
Table 1) (3, 4). These polymorphic VTs of LC I form the ‘de novo’
VF episodes detected by LC II. This ‘arrhythmia shift’ of LC II is
also indicated by the data showing that applying arrhythmia
definitions of LC II reduced the number of VT episodes and
simultaneously increased the number of VF episodes.
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Interestingly, Observer A found that when arrhythmia
definitions of LC II were applied, the cumulative number of VT
and VF episodes was greater than the respective value obtained
according to LC I. The phenomenon of ‘arrhythmia
fragmentation’ is most likely the reason behind this result. LC II
introduced the concept of the importance of ‘diastolic pause’.
According to LC II, “if an arrhythmia is interrupted by an
identifiable pause or quiescence (a ‘diastolic pause’, or a flat
isoelectrical line) that is longer than the prevailing sinus rate (or
idioventricular rate if the AV node is blocked) then it makes
more sense to classify each arrhythmia present before and after
the pause as separate events” (4). This concept enables an
arrhythmia episode to be fragmented into many shorter
arrhythmia episodes. Consequently, the number of VT and VF
episodes measured according to LC I can be affected by
‘arrhythmia fragmentation’ when the same arrhythmias are
evaluated according to LC II. However, the increase in VF
incidence and the reduction in VF onset time caused by LC II
can only be explained by the ‘arrhythmia shift’ phenomenon, and
‘arrhythmia fragmentation’ could not contribute to these results.
It can be concluded that the ‘arrhythmia shift’ caused by LC II is
responsible for the only moderate intra-observer agreement on
VF incidence values obtained according to LC I and LC II.
Applying the ventricular fibrillation definition of LC II may
change the conclusions of pharmacological investigations
Applying VF definition of LC II qualitatively changed
conclusions about the pharmacological effect of flecainide by
questioning the significant antifibrillatory effect of the drug seen
when the VF definition of LC I was applied. The effectiveness of
flecainide against ischaemic VF is not well characterized as
results of previous investigations are confounding (10-14). Thus,
it is not possible to decide which VF definition can provide data
that describes the real face of this drug. However, our results
provide the first clear cut evidence that by changing the
definition of VF the analysis of the same ECG recordings may
yield a completely different conclusion.
The analysis of the VF onset times in the first set of
experiments showed that application of the VF definition of LC II
increases VF detection in all groups, not only in the flecainide-
treated group, but even in the quinidine- and lidocaine-treated
groups and also in the control group. These results imply that the
change in VF definition may retrospectively change the results of
previous pharmacological studies analysed according to LC I. As
mentioned earlier, over 1000 studies have already based their
conclusions on data obtained according to the definitions of LC I.
Changing the definition of VF may invalidate the conclusions of
many of these previous investigations, and also make it impossible
to compare future results that will have been obtained according
to LC II to previous results obtained according to LC I.
Effect of K+ on ventricular fibrillation incidence, application of
the ventricular fibrillation definition of LC II may invalidate
well-accepted physiological and pathophysiological concepts
and studies based on these concepts
Hyperkalaemia can occur in various experimental and
clinical settings (15-17). The physiological and
pathophysiological effects of potassium in the development of
arrhythmias have been intensively studied in earlier
investigations. Arrhythmias following coronary occlusion may
depend on factors such as serum potassium, i.e. higher
potassium concentrations reduce the incidence of ischaemic VF
in rats (18). Hyperkalaemia is antiarrhythmic during myocardial
ischemia and infarction in man; serum potassium concentrations
obtained on admission to hospital were inversely related to the
incidence of ventricular fibrillation (19). An association between
low serum potassium concentrations and ventricular arrhythmias
has also been observed by a number of investigators (20) and an
increased frequency of ventricular fibrillation in patients with
low serum potassium concentrations was also demonstrated
(21). Furthermore, in the GISSI-2 trial, the incidence of VF
among patients with a serum potassium < 3.6 mEq/L was nearly
twice that seen in patients with a higher serum potassium levels
(22). Only one of the above mentioned investigations (18) used
the VF definition of LC I, still there was a good agreement
between these studies on their results about the effect of
potassium on ischaemic VF. Thus, it can be concluded that the
effect of potassium on ischaemic VF is independent of the VF
definition of LC I. However, based on the results of the above
mentioned investigations and the results of several other
previous experimental and clinical investigations, it is now
widely accepted that the incidence of ischaemic VF inversely
correlates with the potassium concentration (3, 4, 18, 23).
When we analysed the effect of K+ concentration on VF
incidence in the control groups and applied the VF definition of
LC I, results were in a good agreement with the above mentioned
experimental and clinical data. This analysis showed that VF
incidence was significantly lower in the control group perfused
with Krebs solution containing 5 mM K+ than that in the control
group perfused with 3 mM K+. However when we applied the
VF definition of LC II, the VF incidence was very high in the
control groups irrespective of the K+ concentration of the Krebs
solution. This suggests that increased sensitivity of VF detection
according to LC II coincided with markedly reduced specificity.
Consequently, application of VF definition of LC II substantially
changed the conclusion about the physiological and
pathophysiological effects of K+ concentration on VF
development. Present results provide the first clear-cut evidence
that applying VF definition of LC II may change the conclusion
not only in pharmacological but also in physiological and
pathophysiological arrhythmia investigations.
Importantly, application of the VF definition of LC II would
totally invalidate the whole proarrhythmia investigation with 5
mM K+ in the perfusate in 3rd and 4th set of experiments in the
original investigation (5,6), as increased VF incidence in the
control hearts perfused with 5 mM K+ does not provide scope for
examining profibrillatory effects of the test drugs. Present results
show that application of the VF definition of LC II may
invalidate a widely known and accepted concept of
pathophysiology of arrhythmia development, and also invalidate
earlier investigations based on this concept. This is a warning
sign, which suggests that the tachyarrhythmia (VT and VF)
definitions of LC II should be abandoned or at least amended in
order to provide greater compatibility with the results of earlier
investigations.
Excellent inter-observer agreement with ventricular fibrillation
definition of LC I, smaller inter-observer agreement with
ventricular fibrillation definition of LC II
Present investigation provides a strong evidence that VF
results are well reproducible and the inter-observer agreement is
high, when the VF definition of LC I is applied. This suggests
that the VF definition of LC I is clear and it is not necessary to
be changed in order to provide greater objectivity during
arrhythmia evaluation, which was one of the main aims of
introducing the new VF definition of LC II (4). This aim was
clearly not fulfilled by the new VF definition of LC II, as
applying VF definition of LC II resulted in less inter-observer
agreement on VF incidence. Furthermore, VT definition of LC II
did not remarkably improve inter-observer agreement on VT
incidence. These suggest that applying VT and VF definitions of
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LC II does not improve compatibility of the results of various
research groups and investigators, which further emphasizes the
need for an amendment of the VT and VF definitions of LC II.
Conclusions
Present investigation provides the first clear-cut evidence that
arrhythmia results obtained by applying ventricular
tachyarrhythmia definitions of LC I and LC II are not compatible
in Langendorff perfused rat hearts. This calls for further research
in order to test the validity of the arrhythmia definitions of LC II
in other species and models, too. Nevertheless, present results
indicate that applying VF definition of LC II may change the
conclusion of previous pharmacological, physiological and
pathophysiological arrhythmia investigations. The reason behind
this is that VF class of LC II incorporated and enlarged the VF
class defined by LC I. The enlarged VF category of LC II
substantially increases the sensitivity of VF detection, but it
coincides with markedly reduced specificity. Furthermore,
present investigation provides an evidence that VF incidence
results are well reproducible and the inter-observer agreement is
high, when the VF definition of LC I is applied. However,
applying VF definition of LC II may reduce inter-observer
agreement on VF incidence. Thus, it is concluded that VT and VF
definitions of LC II should be amended in order to allow better
inter-observer agreement and greater compatibility with the
results of earlier investigations obtained by applying arrhythmia
definitions of LC I. However, any modified definitions should be
subjected to research in order to test their validity.
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